Midatech Pharma Plc VE/BAIIA
Quel est le VE/BAIIA de Midatech Pharma Plc?
Le VE/BAIIA de Midatech Pharma Plc est 0.40
Quelle est la définition de VE/BAIIA?
VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
VE/BAIIA des entreprises dans Health Care secteur sur LSE par rapport à Midatech Pharma Plc
Que fait Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Entreprises avec ve/baiia similaire à Midatech Pharma Plc
- Northern Bitcoin AG a VE/BAIIA de 0.39
- Jilin Province Huinan Changlong Bio-pharmacy a VE/BAIIA de 0.39
- Cassowary Capital a VE/BAIIA de 0.39
- SciPlay a VE/BAIIA de 0.40
- Mmtec a VE/BAIIA de 0.40
- Meat-Tech 3D Ltd a VE/BAIIA de 0.40
- Midatech Pharma Plc a VE/BAIIA de 0.40
- Teras Resources a VE/BAIIA de 0.40
- WestStar Industrial a VE/BAIIA de 0.40
- Gulfport a VE/BAIIA de 0.40
- SDX Plc a VE/BAIIA de 0.40
- Harpoon Therapeutics a VE/BAIIA de 0.41
- Litho Formas, S.A a VE/BAIIA de 0.41